


Dab/Tram (dabrafenib and trametinib)

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



More serious and disabling adverse events observed



#### Other adjustments



Dab/Tram (dabrafenib and trametinib)

### SCORE

#### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Advanced NSCLC with a BRAF V600 mutation

Experimental Arm: Dab/Tram (dabrafenib and trametinib)

Control Arm: Single arm



